StockData
Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc. (ELVN) stock

ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$46.85−0.77 (-1.62%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield –

Enliven Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Enliven Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$124.25M. For fiscal 2025 it was -$119.36M.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$119.36M–
FY2024Dec 31, 2024-$104.25M–
FY2023Dec 31, 2023-$83.23M–
FY2022Dec 31, 2022-$38.59M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$37.20M–
Q1 FY2026Mar 31, 2026-$27.81M–
Q4 FY2025Dec 31, 2025-$34.20M–
Q3 FY2025Sep 30, 2025-$25.03M–
Q2 FY2025Jun 30, 2025-$28.50M–
Q1 FY2025Mar 31, 2025-$31.62M–
Q4 FY2024Dec 31, 2024-$26.83M–
Q3 FY2024Sep 30, 2024-$26.99M–
Q2 FY2024Jun 30, 2024-$24.52M–
Q1 FY2024Mar 31, 2024-$25.91M–
Q4 FY2023Dec 31, 2023-$22.65M–
Q3 FY2023Sep 30, 2023-$24.17M–
Q2 FY2023Jun 30, 2023-$20.06M–
Q1 FY2023Mar 31, 2023-$16.35M-153.9%
Q4 FY2022Dec 31, 2022-$10.11M–
Q3 FY2022Sep 30, 2022-$10.87M–
Q2 FY2022Jun 30, 2022-$8.96M–
Q1 FY2022Mar 31, 2022$30.32M–

More Enliven Therapeutics figures

See a number that looks wrong?